Current review of cytomegalovirus in renal transplantation

Minerva Urologica e Nefrologica

Volumn 53, Issue 3, 2001, Pages 145-158

  Lopez Rocafort, L ^a   Brennan, D C ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

Diagnosis Cytomegalovirus infections; Kidney transplantation Cytomegalovirus infections; Therapy

Indexed keywords

ACICLOVIR; CYTOMEGALOVIRUS ANTIBODY; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; VALACICLOVIR; VALGANCICLOVIR;

ANTIGEN DETECTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG INDUCED DISEASE; GENE AMPLIFICATION; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NEUTROPENIA; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; REVIEW; RNA ANALYSIS; SEPSIS; VIRUS DIAGNOSIS;

CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HUMANS; KIDNEY TRANSPLANTATION;

EID: 0035673652     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Smith MG. Propagation in tissue cultures of cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med 1956;92:424-30.
2. nd edition. St. Louis: Mosby-Year Book, Inc., 1991:889-924.
3. Larsson S, Soderberg-Naucler C, Moller E. Productive cytomegalovirus (CMV) infection exclusively in CD13-positive peripheral blood mononuclear cells from CMV infected individuals: implications for prevention of CMV transmission. Transplantation 1998;65:411-5.
4. Nakayama K. Furin, a subtilisin/Kex2p-like pro-protein convertase. Biochem J 1997;327(Pt3):625-35.
5. Jean F, Thomas L, Molloy SS, Liu G, Jarvis MA, Nelson JA et al. A protein-based therapeutic for human cytomegalovirus infection. Proc Natl Acad Sci 2000;97: 2864-9.
6. Geist U, Dai LY. Immediate early gene 2 of human cytomegalovirus increases interleukin 2 receptor-a gene expression. J Investig Med 2000;48:60-5.
7. Geist U, Monick MM, Stinski MF, Hunninghake GW. Cytomegalovirus immediate early genes prevent the inhibitory effect of tyclosporin A on interleukin 2 gene transcription. J Clin Invest 1992;90:2136-40.
8. Craigen JL, Grundy JE. Cytomegalovirus induced Lip-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation 1996;62: 1102-8.
9. Ploegh HL. Viral strategies of immune evasion. Science 1998;280:248-53.
10. Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science 2000;287: 1031-3.
11. Kotenko SV, Saccani S, Isotova LS, Mirochnitchenko OV, Pestka S. Human cytomegalovirus harbors its own unique B-10 homolog (CMVIL-10). Proc Natl Acad Sci 2000;97:1695-700.
12. Brennan DC, Singer GG. Infectious complications in renal transplantation. In: Malluche HH, Sawaya BP, Hakim RM, Sayegh MH, Ismail N, editors. Clinical Nephrology Dialysis and Transplantation. Landshut, Germany: Bosch-Druck, 1999:1-24.
13. Sai IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000;13: 83-121.
14. Nevins TE, Dunn DL. Use of ganciclovir for cytomegalovirus infection. J Am Soc Nephrol 1992;2012 Suppl):S270-3.
15. ter Meulen CG, Wetzels JF, Hilbrands LB. The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 2000;15(5):711-4.
16. Sarmiento JM, Dockrell DH, Schwab TR, Munn SR, Paya CV. Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients. Clin Transplant 2000;14(2):136-8.
17. Pirsch JD. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. Transplantation 1999;68(8): 1203-5.
18. Hengster P, Pescovitz MD, Hyatt D, Margreiter R. Cytomegalovirus infections after treatment with daclizumab, and anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group. Transplantation 1999;68(2):310-3.
19. Kode RK, Kumar AM, Pankewycz O, Damask AM, Seirka D. Lam A et al. Simulect induction significantly decreases CMV infection in kidney recipients compared to OKT3. Transplant Proc 2001;33(1-2):1268-9.
20. Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000:69(7):1252-60.
21. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67(7):1036-42.
22. Schnitzler MA, Woodward RS, Brennan DC, Spitznagel EL, Dunagan WC, Bailey TC. The effects of cytomegalovirus serology on graft and recipient survival in cadaveric renal transplantation: implications for organ allocation. Am J Kidney Dis 1997;29:428-34.
23. Schnitzler MA, Woodward RS, Brennan DC, Spitznagel FL, Dunagan WC, Bailey TC. Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: implications for donor selection. Surgery 1997;121:563-8.
24. Kern F, Ode-Hakim S, Nugel H, Vogt K, Volk HD, Reinke P. Peripheral T cell activation in long-term renal transplant patients: concordant upregulation of adhesion molecules and cytokine gene transcription. J Am Soc Nephrol 1996; 11: 2476-82.
25. Humar A, Gillingham K, Payne WD, Dunn DL, Sutherland DE, Matas AJ. Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 1999;68(12):1879-83.
26. Holma K, Tornroth T, Gronhagen-Riska C, Lautenschlager I. Expression of the cytomegalovirus genome in kidney allografts during active and latent infection. Transplant Int 2000;13(Suppl 1):S363-5.
27. Toupance O, Bouedjoro-Camus MC, Carquin J, Novella JL, Lavaud S, Wynckel A et al. Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses. Transplant Int 2000;13(6):413-9.
28. Dickenmann MJ, Cathomas G, Steiger J, Mihatsch MJ, Thiel G, Tamm M. Cytomegalovirus infection and graft rejection in renal transplantation. Transplantation 2001;71(6):764-7.
29. Xhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T et al. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996;335:624-30.
30. Humar A, Gillingham K, Payne WD, Sutherland DE, Matas AJ. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 2000;70(2):310-3.
31. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T et al. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 1994;265:391-4.
32. Streblow DN, Soderberg-Naucler C, Vieira J, Smith P, Wakahayashi F, Ruchti F et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 1999;99:511-20.
33. Zhou YF, Guetta E, Yu ZX, Finkel T, Epstein SF. Human cytomegalovirus increases modified low density lipoprotein uptake and scavenger receptor mRNA expression in vascular smooth muscle cells. J Clin Invest 1996;98:2129-38.
34. Birk PE, Chavers BM. Does cytomegalovirus cause glomerular injury in renal allogratt recipients? J Am Soc Nephrol 1997;8:1801-8.
35. Miller BW, Hmiel SP, Schnitzler MA, Brennan DC. Cyclosporine as cause of thrombotic microangiopathy after renal transplantation. Am J Kidney Dis 1997;29: 813-4.
36. Jeejeebhoy FM, Zaltzman JS. Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy. Transplantation 1998;65:1645-8.
37. Hochstetler LA, Flanigan MJ, Lager DJ. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy. Am J Kidney Dis 1994;23:444-50.
38. Pouria S, Stale Ol, Wong W, Hendry BM. CMV infection is associated with transplant renal artery stenosis. QJM 1998;91(3):185-9.
39. Osman HK, Peiris JS, Taylor CE, Warwicker P, Jarrett RF, Madeley CR. Cytomegalovirus disease in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression? J Med Virol 1996;48(4):295-301.
40. Ratnamohan VM, Chapman J, Howse H, Bovington K, Robertson P, Byth K et al. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. Transplantation 1998;66(7):877-82.
41. Emery VC, Human herpesviruses 6 and 7 in solid organ transplant recipients. Clin Infect Dis 2001;32(9): 1357-60.
42. Tong CY, Bakran A, Williams H, Cheting CY, Peiris JS. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients. Transplantation 2000;70(1):21.3-6.
43. Brennan DC, Storch GA, Singer GG, Lee L, Rueda J, Schnitzier MA. The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir. J Infect Dis 2000;181(5): 1557-61.
44. Mendez JC, Dockrell DH, Espy MJ, Smith TF, Wilson JA, Harmsen WS et al. Human beta-herpesvirus interactions in solid organ transplant recipients. J Infect Dis 2001;183(2):179-84.
45. st edition. New York: Harcourt Brace & Company, 2000: 203-32.
46. Goossens VJ, Blok MJ, Christiaans MH, Sillekens P, Middeldorp JM, Bruggeman CA. Early detection of cytomegalovirus in renal transplant recipients: comparison of PCR, NASBA, pp65 antigenemia, and viral culture. Transplant Proc 2000;32(1):155-8.
47. Gema G, Baldanti F, Middeldorp J, Lilleri D. Use of CMV transcripts for monitoring of CMV infections in transplant recipients. Int J Antimicrob Agents 2000; 16(4):455-60.
48. Brennan DC, Garlock KA, Lippmann BA, Buller RS, Gaudreault-Keener M, Lowel JA et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997;8:118-125.
49. Roberts TC, Buller RS, Gaudreault-Keener M, Sternhell KE, Garlock K, Singer GG et al. Effects of storage temperature and time on qualitative and quantitative detection of cytomegalovirus in blood specimens by shell vial culture and PCR. J Clin Microbiol 1997;35:2224-8.
50. Wolf DG, Spector SA. Early diagnosis of human cytomegalovirus disease in transplant recipients by DNA amplification in plasma. Transplantation 1993;56(2): 330-4.
51. Pellegrin I, Garrigue I, Ekovevi D, Couzi L, Merville P, Merel P et al. New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients. J Infect Dis 2000;182(1):36-42.
52. Toyoda M, Carlos JB, Galera OA, Galfayan K, Zhang X, Sun Z. et al. Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients. Transplantation 1997;63: 957-63.
53. Roberts TC, Brennan DC, Buller RS, Gaudreault-Keener M, Schnitzler MA, Sternbell KE et al. Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 1998;178:626-35.
54. Tong CY, Cuevas LE, Williams H, Bakran A. Prediction and diagnosis of cytomegalovirus disease in renal transplant recipients using qualitative and quantitative polymerase chain reaction. Transplantation 2000:69(5):985-91.
55. Crumpacker CS, Ganciclovir. N Engl J Med 1996;335: 721-9.
56. Lippmann BJ, Brennan DC, Wong J, Lowell JA, Singer GG, Howard TK. Are varicella zoster and herpes simplex sentinel lesions for cytomegalovirus in renal transplant recipients? [letter]. Lancet 1995;346:914-5.
57. Waid TH, McKeown JW. Cytomegalovirus hyperimmune globulin for CMV disease refractory to ganciclovir in renal transplantation. Transplant Proc 1995;27:46.
58. Ljungman P, Cordonnier C, Einsele H, Bender-Gotze C, Bosi A, Dekkar A et al. Use ot intravenous immune globulin in addition to antiviral therapy in the treatment of CMV gastrointestinal disease in allogeneic hone marrow transplant patients. A report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1998;21:473-6.
59. Bailey TC. Prevention of cytomegalovirus disease. Semin Respir Infect 1993;8:225-32.
60. Hibberd PL, Tolkoff-Rubin NE, Conti D, Thistlewaite JR, Neylan JF, Snydman DR et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: A randomized controlled trial. Ann Intern Med 1995;123:18-26.
61. Snydman DR, Werner BG, Heinze-Lacey B, Bernardi VP, Tilney NL, Kirkman RL et al. Use of cytomegalovirus immune-globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987;317: 1049-54.
62. McCune TR, Johnson HK, MacDonell RC Jr, Richie RE, Nylander WA, VanBuren DH et al. The effect of polyimmune gammaglobulin for prophylaxis against reactivation cytomegalovirus infection in kidney and kidney/pancreas transplant recipient. I Am Soc Nephrol 1992;2:1469-74.
63. Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - a meta-analysis. Clin Transplant 1994;8:10-8.
64. Tyan D, Li V, Czer L, Trento A, Jordan SC. Intravenous immunoglobulin suppression of HLA alloantibody in highly-sensitized transplant candidates and transplantation with a histoincompatible organ. Transplantation 1994;57:553-62.
65. Sivasai KSR, Mohanakumar T, Phelan D, Martin S, Anstey ME, Brennan DC. Cytomegalovirus immune globulin intravenous (human) administration modules immune response to alloantigens in sensitized renal transplant candidates. Clin Exp Immunol 2000;119:559-65.
66. Ellie F, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure. N Engl J Med 1992;327:1032-3.
67. Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts. N Engl J Med 1989;320:1381-7.
68. Kletzmayr J, Kotzmann H, Popow-Kraupp T, Kovarik J, Klauser R. Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients. J Am Soc Nephrol 1996;7:325-30.
69. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992;326:1182-6.
70. Winston DJ, Wirin D, Shaked A, Busuttil RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995;346:69-74.
71. Brennan DC, Garlock KA, Singer GG, Schnitzler MA, Lippmanr BJ, Buller RS et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997;64:1843-6.
72. Flechner SM, Avevy RK, Fisher R, Mastroianni BH. Papajcik DA, O'Malley M et al. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 1998;66: 1682-8.
73. Gane E, Saliba F, Valdecasas GJ, O'Grady J, Pescovitz MD, Lyman S et al. Randomized trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group. Lancet 1997;350:1729-33.
74. Aweeka FT, Jacobson MA, Martin-Munley S, Hedman A, Schoenfeld P, Omachi R et al. Effect of renal disease and hemodialysis on foscarnet pharmacokinetics and dosing recommendations. J Acquir Immune Defic Syndr Hum Retrovirol 1999;20:350-7.
75. Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. The International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. N Engl J Med 1999;340:1462-70.
76. Pescovitz MD, Rabkin J, Merion R, Paya C, Pirsch J, Freeman R et al. Valganciclovir provides ganciclovir plasma exposure similar to IV ganciclovir in transplant recipients [abstract]. Transplantation 1999;67:S126.
77. Plotkin SA, Starr SK, Friedman HM, Brayman K, Harris S, Jackson S et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 1991;114:525-31.
78. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K. Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis 1990;12: S827-38.
79. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH Jr. Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
80. Erice A, Gil Roda C, Perez JL, Balfour HH Jr, Sannerud KJ, Hanson MN et al. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997;175:1087-92.
81. Kruger RM, Shannon WD, Arens MQ, Lynch JP, Storch GA, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 1999;68:1272-9.
82. Bienvenu B, Thervet E, Bedrossian J, Scieux C, Mazeron MC, Thouvenot D et al. Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant incipient. Transplantation 2000;69:182-4.
83. Rosen HR, Benner KG, Flora KD, Rabkin JM, Orloff SL, Olyaei A et al. Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation. Transplantation 1997;63: 476-8.
84. Pescovitz MD, Pruett TL, Gonwa T, Brook B, McGory R, Wicker K et al. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 1998;66:1104-7.
85. Grossi P, Baldanti F. Treatment of ganciclovir-resistant human cytomegalovirus infection. J Nephrol 1997;10: 146-51.